3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
64
Neoplasms, Plasma Cell
6
Neoplasms
6
Recurrence
5
Renal Insufficiency
3
Paraproteinemias
3
Immunoglobulin Light-chain Amyloidosis
3
Hematologic Diseases
3
Smoldering Multiple Myeloma
2
Neoplasms by Histologic Type
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Blood Protein Disorders
2
Purpura
1
Neoplasm, Residual
1
Nausea
1
Monoclonal Gammopathy of Undetermined Significance
1
Macroglossia
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphadenopathy
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hepatomegaly
1
Hematologic Neoplasms
1
Gastrointestinal Hemorrhage
1
Diarrhea
1
Interventions
Lenalidomide
5
Dexamethasone
4
fludarabine phosphate
2
daratumumab
2
Whole-Body Irradiation
2
Cyclophosphamide
2
Calcium Dobesilate
2
talquetamab
1
selinexor
1
ixazomib
1
isatuximab
1
fludarabine
1
Transplantation, Autologous
1
Sirolimus
1
Rituximab
1
Mycophenolic Acid
1
Melphalan
1
Bortezomib
1
Blood Specimen Collection
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
isatuximab
×
Plasma cell
×
Clear all
NCT05690984
2026-03-16
EMAT
Medical College of Wisconsin
Phase 2
Active not recruiting
30 enrolled